Boehringer Ingelheim Will Acquire Actimis | Chemical & Engineering News
Volume 86 Issue 25 | p. 17 | Concentrates
Issue Date: June 23, 2008

Boehringer Ingelheim Will Acquire Actimis

Department: Business

Germany's Boehringer Ingelheim has agreed to acquire Actimis Pharmaceuticals, a privately held biotech company in San Diego. Spun off from Bayer in 2004, Actimis focuses on small-molecule drugs for respiratory, inflammatory, and autoimmune diseases. BI will acquire the company through a structured buyout, purchasing shares according to development milestones reached by Actimis' lead compound, called AP768, for treating asthma. If AP768, now in Phase I clinical trials, successfully advances into Phase III, BI will own 100% of Actimis' shares in a deal totaling $515 million.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment